bluuebunny/crossref_metadata_2025_split huggingface dataset:
Males and females contribute differently to the evolution of habitat segregation driven by hybridization
Authors: Kyogoku Daisuke , Yamaguchi Ryo 
Published: February 2023

AbstractCostly heterospecific mating interactions, such as hybridization, select for prezygotic reproductive isolation. One of the potential traits responding to the selection arising from maladaptive hybridization is habitat preference, whose divergence results in interspecific habitat segregation. Theoretical studies have so far assumed that habitat preference is a sexually shared trait. However, male and female habitat preferences can experience different selection pressures. Here, by combining analytical and simulation approaches, we theoretically examine the evolution of sex‐specific habitat preferences. Habitat segregation can have demographic consequences, potentially generating eco‐evolutionary dynamics. We thus explicitly consider demography in the simulation model. We also vary the degrees of species discrimination to examine how mate choice influences the evolution of habitat preferences. Results show that both sexes can reduce hybridisation risk by settling in the habitats where abundant conspecific mates reside. However, when females can discriminate species, excess conspecific male aggregation intensifies male–male competition for mating opportunities, posing an obstacle to conspecific aggregation. Meanwhile, conspecific female aggregation attracts conspecific males, by offering the mating opportunity. Therefore, under effective species discrimination, females play a leading role in initiating habitat use divergence. Simulations typically result in either the coexistence with established habitat segregation or the extinction of one of the species. The former result is especially likely when the species differ to some extent in habitat preferences upon secondary contact. Our results disentangle the selection pressures acting on male and female habitat preferences, deepening our understanding of the evolutionary process of habitat segregation due to hybridization.
Heat transfer modeling during high‐humidity hot air impingement blanching of grapes
Authors: Rezaei Hossein , Sadeghi Morteza 
Published: February 2023

AbstractDuring high‐humidity hot air impingement blanching (HHAIB) of fruits and vegetables, the process effect on the product and subsequent process depends on the operating fluid parameters. In this regard, heat transfer phenomenon during applying the pretreatment is not well known. In this study, the mechanisms of heat transfer during the HHAIB of grape berries were investigated via developing an appropriate mathematical model. Numerical simulation of the model was performed using COMSOL software at temperature of 110°C, fluid velocities of 2, 6, and 10 m s−1, and relative humidities of 20%, 40%, 60%, and 80%. The heat transfer caused by the impinging jet and condensation on the grape surface were considered. The center and surface temperature of the grape berries were predicted. Taking the appropriate heat transfer rate and uniformity of temperature distribution in grape berries into account, the relative humidity range of 40%–60% and the velocity of 10 m s−1 were selected for the process. Comparison of the predicted and measured values for the center temperature of the grape berry statistically validated the simulation task with a determination coefficient (R2) of 0.993 and root mean square error of 1.347.Practical ApplicationsNowadays, the demand for organic foods has increased. The high‐humidity hot air impingement blanching (HHAIB) is a safe, effective, and controllable nonchemical method that can be used instead of chemical pretreatment in raisin production. In terms of applying the HHAIB pretreatment for grape drying, little research has been done. Thus, there is still no complete understanding of the heat transfer during its application. Numerical simulations are beneficial tools for accurate designing and optimization of thermal processes. Thus, it is necessary to use mathematical modeling to understand HHAIB mechanisms for industrialization.
Insights for lake restoration and water supply management in hilly regions
Authors: Kumar Arun , Goyal Kirti , Pande P. K. 
Published: February 2023

AbstractWater resources around the world are facing serious threats attributable to various natural and anthropogenic activities. Civil societies around the world, including India, are facing increasing difficulty in the allocation and sustainable use of their available water resources. Many lakes and rivers, the major surface water sources in India, are highly polluted and on the verge of depletion. Accordingly, there is a growing interest in protecting the ecosystem services provided by the lakes and rivers using several management approaches for lake rejuvenation and conservation. A similar study focusing on water supply situation and its restoration was performed in Nainital, a major hill town located in the state of Uttarakhand. The lake water level has been declining in recent years, raising serious concerns. To address this issue, a plan has been developed to address the decreasing lake level and conserving this vital water supply source for the town. The present study provides an integrated framework enabling conservation practitioners to strategically implement water conservation actions to balance both the ecosystem and societal water needs.
Respiratory viruses: New frontiers—a Keystone Symposia report
Authors: Cable Jennifer , Sun Jie , Cheon In Su , Vaughan Andrew E. , Castro Italo A. , Stein Sydney R. , López Carolina B. , Gostic Katelyn M. , Openshaw Peter J. M. , Ellebedy Ali H. , Wack Andreas , Hutchinson Edward , Thomas Mallory M. , Langlois Ryan A. , Lingwood Daniel , Baker Steven F. , Folkins Melanie , Foxman Ellen F. , Ward Andrew B. , Schwemmle Martin , Russell Alistair B. , Chiu Christopher , Ganti Ketaki , Subbarao Kanta , Sheahan Timothy P. , Penaloza‐MacMaster Pablo , Eddens Taylor 
Published: February 2023

AbstractRespiratory viruses are a common cause of morbidity and mortality around the world. Viruses like influenza, RSV, and most recently SARS‐CoV‐2 can rapidly spread through a population, causing acute infection and, in vulnerable populations, severe or chronic disease. Developing effective treatment and prevention strategies often becomes a race against ever‐evolving viruses that develop resistance, leaving therapy efficacy either short‐lived or relevant for specific viral strains. On June 29 to July 2, 2022, researchers met for the Keystone symposium “Respiratory Viruses: New Frontiers.” Researchers presented new insights into viral biology and virus–host interactions to understand the mechanisms of disease and identify novel treatment and prevention approaches that are effective, durable, and broad.
Boron supply restores aluminum‐blocked auxin transport by the modulation of PIN2 trafficking in the root apical transition zone
Authors: Tao Lin , Xiao Xiaoyi , Huang Qiuyu , Zhu Hu , Feng Yingming , Li Yalin , Li Xuewen , Guo Zhishan , Liu Jiayou , Wu Feihua , Pirayesh Niloufar , Mahmud Sakil , Shen Ren Fang , Shabala Sergey , Baluška František , Shi Lei , Yu Min 
Published: February 2023

SUMMARYThe supply of boron (B) alleviates the toxic effects of aluminum (Al) on root growth; however, the mechanistic basis of this process remains elusive. This study filled this knowledge gap, demonstrating that boron modifies auxin distribution and transport in Al‐exposed Arabidopsis roots. In B‐deprived roots, treatment with Al induced an increase in auxin content in the root apical meristem zone (MZ) and transition zone (TZ), whereas in the elongation zone (EZ) the auxin content was decreased beyond the level required for adequate growth. These distribution patterns are explained by the fact that basipetal auxin transport from the TZ to the EZ was disrupted by Al‐inhibited PIN‐FORMED 2 (PIN2) endocytosis. Experiments involving the modulation of protein biosynthesis by cycloheximide (CHX) and transcriptional regulation by cordycepin (COR) demonstrated that the Al‐induced increase of PIN2 membrane proteins was dependent upon the inhibition of PIN2 endocytosis, rather than on the transcriptional regulation of the PIN2 gene. Experiments reporting on the profiling of Al3+ and PIN2 proteins revealed that the inhibition of endocytosis of PIN2 proteins was the result of Al‐induced limitation of the fluidity of the plasma membrane. The supply of B mediated the turnover of PIN2 endosomes conjugated with indole‐3‐acetic acid (IAA), and thus restored the Al‐induced inhibition of IAA transport through the TZ to the EZ. Overall, the reported results demonstrate that boron supply mediates PIN2 endosome‐based auxin transport to alleviate Al toxicity in plant roots.
Nonlocal differential equations with (p,q)$ {(p,q)}$ growth
Authors: Goodrich Christopher S. 
Published: February 2023

AbstractThe author considers a class of nonlocal convolution‐type ordinary differential equations of the form
where is a continuous function satisfying growth — that is, there exist constants , and such that
where . Existence of at least one positive solution to this equation when subjected to given boundary data is studied by means of topological fixed point theory.
Efficacy, safety, and tolerability of antidepressants for pain in adults: overview of systematic reviews
Authors: Ferreira Giovanni E , Abdel-Shaheed Christina , Underwood Martin , Finnerup Nanna B , Day Richard O , McLachlan Andrew , Eldabe Sam , Zadro Joshua R , Maher Christopher G 
Published: February 2023

Abstract

Objective
To provide a comprehensive overview of the efficacy, safety, and tolerability of antidepressants for pain according to condition.

Design
Overview of systematic reviews.

Data sources
PubMed, Embase, PsycINFO, and the Cochrane Central Register of Controlled Trials from inception to 20 June 2022.

Eligibility criteria for selecting studies
Systematic reviews comparing any antidepressant with placebo for any pain condition in adults.

Data extraction and synthesis
Two reviewers independently extracted data. The main outcome measure was pain; for headache disorders it was frequency of headaches. Continuous pain outcomes were converted into a scale of 0 (no pain) to 100 (worst pain) and were presented as mean differences (95% confidence intervals). Dichotomous outcomes were presented as risk ratios (95% confidence intervals). Data were extracted from the time point closest to the end of treatment. When end of treatment was too variable across trials in a review, data were extracted from the outcome or time point with the largest number of trials and participants. Secondary outcomes were safety and tolerability (withdrawals because of adverse events). Findings were classified from each comparison as efficacious, not efficacious, or inconclusive. Certainty of evidence was assessed with the grading of recommendations assessment, development, and evaluation framework.

Results
26 reviews (156 unique trials and >25 000 participants) were included. These reviews reported on the efficacy of eight antidepressant classes covering 22 pain conditions (42 distinct comparisons). No review provided high certainty evidence on the efficacy of antidepressants for pain for any condition. 11 comparisons (nine conditions) were found where antidepressants were efficacious, four with moderate certainty evidence: serotonin-norepinephrine reuptake inhibitors (SNRIs) for back pain (mean difference −5.3, 95% confidence interval −7.3 to −3.3), postoperative pain (−7.3, −12.9 to −1.7), neuropathic pain (−6.8, −8.7 to −4.8), and fibromyalgia (risk ratio 1.4, 95% confidence interval 1.3 to 1.6). For the other 31 comparisons, antidepressants were either not efficacious (five comparisons) or the evidence was inconclusive (26 comparisons).

Conclusions
Evidence of efficacy of antidepressants was found in 11 of the 42 comparisons included in this overview of systematic reviews—seven of the 11 comparisons investigated the efficacy of SNRIs. For the other 31 comparisons, antidepressants were either inefficacious or evidence on efficacy was inconclusive. The findings suggest that a more nuanced approach is needed when prescribing antidepressants for pain conditions.

Systematic review registration
PROSPERO CRD42022311073.
Clinical outcomes of myocarditis after SARS-CoV-2 mRNA vaccination in four Nordic countries: population based cohort study
Authors: Husby Anders , Gulseth Hanne Løvdal , Hovi Petteri , Hansen Jørgen Vinsløv , Pihlström Nicklas , Gunnes Nina , Härkänen Tommi , Dahl Jesper , Karlstad Øystein , Heliö Tiina , Køber Lars , Ljung Rickard , Hviid Anders 
Published: February 2023

ObjectiveTo investigate the clinical outcomes of myocarditis associated with mRNA vaccines against the SARS-CoV-2 virus compared with other types of myocarditis.DesignPopulation based cohort study.SettingNationwide register data from four Nordic countries (Denmark, Finland, Norway, and Sweden), from 1 January 2018 to the latest date of follow-up in 2022.ParticipantsThe Nordic myocarditis cohort; 7292 individuals aged ≥12 years who had an incident diagnosis of myocarditis as a main or secondary diagnosis, in a population of 23 million individuals in Denmark, Finland, Norway, and Sweden.Main outcome measuresHeart failure, or death from any cause within 90 days of admission to hospital for new onset myocarditis, and hospital readmission within 90 days of discharge to hospital for new onset myocarditis. Clinical outcomes of myocarditis associated with SARS-CoV-2 mRNA vaccination, covid-19 disease, and conventional myocarditis were compared.ResultsIn 2018-22, 7292 patients were admitted to hospital with new onset myocarditis, with 530 (7.3%) categorised as having myocarditis associated with SARS-CoV-2 mRNA vaccination, 109 (1.5%) with myocarditis associated with covid-19 disease, and 6653 (91.2%) with conventional myocarditis. At the 90 day follow-up, 62, nine, and 988 patients had been readmitted to hospital in each group (vaccination, covid-19, and conventional myocarditis groups, respectively), corresponding to a relative risk of readmission of 0.79 (95% confidence interval 0.62 to 1.00) and 0.55 (0.30 to 1.04) for the vaccination type and covid-19 type myocarditis groups, respectively, compared with the conventional myocarditis group. At the 90 day follow-up, 27, 18, and 616 patients had a diagnosis of heart failure or died in the vaccination type, covid-19 type, and conventional myocarditis groups, respectively. The relative risk of heart failure within 90 days was 0.56 (95% confidence interval 0.37 to 0.85) and 1.48 (0.86 to 2.54) for myocarditis associated with vaccination and covid-19 disease, respectively, compared with conventional myocarditis; the relative risk of death was 0.48 (0.21 to 1.09) and 2.35 (1.06 to 5.19), respectively. Among patients aged 12-39 years with no predisposing comorbidities, the relative risk of heart failure or death was markedly higher for myocarditis associated with covid-19 disease than for myocarditis associated with vaccination (relative risk 5.78, 1.84 to 18.20).ConclusionsCompared with myocarditis associated with covid-19 disease and conventional myocarditis, myocarditis after vaccination with SARS-CoV-2 mRNA vaccines was associated with better clinical outcomes within 90 days of admission to hospital.
Personalised azithromycin+metronidazole (PAZAZ), in combination with standard induction therapy, to achieve a faecal microbiome community structure and metagenome changes associated with sustained remission in paediatric Crohn’s disease (CD): protocol of a pilot study
Authors: Verburgt Charlotte M , Dunn Katherine A , Otley Anthony , Heyman Melvin B , Verstraete Sofia , Sunseri Withney , Sylvester Francisco , de Meij Tim , Comeau Andre , Langille Morgan , de Jonge Wouter J , Benninga Marc A , Van Limbergen Johan E 
Published: February 2023

IntroductionEarly relapse in Crohn’s disease (CD) is associated with a more severe disease course. The microbiome plays a crucial role, yet strategies targeting the microbiome are underrepresented in current guidelines. We hypothesise that early manipulation of the microbiome will improve clinical response to standard-of-care (SOC) induction therapy in patients with a relapse-associated microbiome profile. We describe the protocol of a pilot study assessing feasibility of treatment allocation based on baseline faecal microbiome profiles.Methods and analysisThis is a 52-week, multicentre, randomised, controlled, open-label, add-on pilot study to test the feasibility of a larger multicontinent trial evaluating the efficacy of adjuvant antibiotic therapy in 20 paediatric patients with mild-to-moderate-CD (10<PCDAI≤37.5; PCDAI, Pediatric Crohn’s Disease Activity Index). SOC induction treatment will be Crohn’s Disease Exclusion Diet+Partial Enteral Nutrition (CDED+PEN). Relapse-associated microbiome signatures will be evaluated using 16S rRNA gene sequencing and a previously generated Bayesian predictive model (BioMiCo) based on baseline stool. At week 4, patients in remission with relapse-associated signatures (group A) will be randomised to CDED+antibiotics (A2) or CDED+PEN alone (A1). Patients in remission without this signature will continue CDED+PEN alone (B). Patients not in remission will receive CDED+antibiotics regardless of their microbiome signature (C). Subjects in group A2 or C will receive a combination of azithromycin 7.5 mg/kg (weeks 4–8: 5 days/week; weeks 9–12: 3 days/week) with metronidazole 20 mg/kg/day (weeks 4–12). Primary outcomes will assess feasibility of treatment allocation and possible efficacy to sustain remission (PCDAI≤10, no need for reinduction). Exploratory outcomes will include changes in PCDAI, inflammatory markers and patient-reported outcomes. We will additionally explore changes in faecal microbiome taxonomic composition between groups.Ethics and disseminationThis study was approved by METC-AMC and CCMO (Netherlands) and IWK Health Centre (Canada). The first version of this protocol was approved by North Carolina Children’s Hospital (USA), Wolfson Medical Centre (Israel). The FDA (USA), Health Canada and Ministry of Health (Israel) have reviewed and approved the protocol. Results will be published in international peer-reviewed journals and summaries will be provided to the funders and participants.Trial registration numberNCT04186247.
Methodology of the brodalumab assessment of hazards: a multicentre observational safety (BRAHMS) study
Authors: Reilev Mette , Jensen Peter Bjødstrup , Ranch Lise Skov , Egeberg Alexander , Furu Kari , Gembert Karin , Hagg David , Haug Ulrike , Karlstad Øystein , Reutfors Johan , Schäfer Wiebke , Schwartz Sarina , Smits Elisabeth , Holthius Emily , Herings Ron , Trifirò Gianluca , Kirchmayer Ursula , Rosa Alessandro Cesare , Belleudi Valeria , Gini Rosa , Støvring Henrik , Hallas Jesper 
Published: February 2023

IntroductionSafe and effective pharmacological treatment is of paramount importance for treating severe psoriasis. Brodalumab, a monoclonal antibody against interleukin (IL) 17 receptor A, was granted marketing authorisation in the EU in 2017. The European Medicines Agency requested a postauthorisation safety study of brodalumab to address potential safety issues raised during drug development regarding major adverse cardiovascular events, suicidal conduct, cancer and serious infections.Methods and analysisBRodalumab Assessment of Hazards: A Multinational Safety is a multicentre observational safety study of brodalumab running from 2017 to 2029 using population-based healthcare databases from Denmark, Sweden, Norway, Netherlands, Germany and three different centres in Italy. A distributed database network approach is used, such that only aggregate data are exchanged between sites.Two types of designs are used: a case-time-control design to study acute effects of transient treatment and a variation of the new user active comparator design to study the effects of transient or chronic treatment. As comparators, inhibitors of TNF-α, inhibitors of IL-12 and IL-23, and other inhibitors of cytokine IL-17A are included.In the self-controlled case-time-control design, the risk of developing the outcome of interest during periods of brodalumab use is compared within individuals to the risk in periods without use.In the active comparator cohort design, new users of brodalumab are identified and matched to new users of active comparators. Potential baseline confounders are adjusted for by using propensity score modelling. For outcomes that potentially require large cumulative exposure, an adapted active comparator design has been developed.Ethics and disseminationThe study is approved by relevant authorities in Denmark, Norway, Sweden, the Netherlands, Germany and Italy in line with the relevant legislation at each site. Data confidentiality is secured by the distributed network approach. Results will be published in peer-reviewed journals.Trial registration numberEUPAS30280.
Diagnostic delay in children with neurodevelopmental conditions attending a publicly funded developmental assessment service: findings from the Sydney Child Neurodevelopment Research Registry
Authors: Boulton Kelsie A , Hodge Marie-Antoinette , Jewell Ailsa , Ong Natalie , Silove Natalie , Guastella Adam J 
Published: February 2023

ObjectivesEarly developmental assessment is crucial for effective support and intervention. This study examined factors that contribute to (a) older child age when caregivers first became concerned about their child’s development and (b) older child age at the point of entry into developmental and diagnostic assessment. We also quantified how factors contributed to risk of children not receiving an assessment by 5 years and considered the acceptability of electronic data capture for families.DesignThis cross-sectional study collected information about caregiver developmental concerns, family history and child characteristics.SettingChildren and families entered a large, publicly funded hospital-based paediatric developmental assessment service.ParticipantsConsecutively enrolled children (N=916) aged 6 months to 17 years with neurodevelopmental concerns and their caregivers.Main outcomes and measuresA developmental history questionnaire completed by caregivers.ResultsThe average age that caregivers identified developmental concerns was 3.0 years of age but the average age of a receiving a developmental assessment was 6.6 years. Only 46.4% of children received a diagnostic assessment by 5 years of age, even though 88.0% of caregivers were concerned about their child’s development by that age. Parental age, relationship status, education level, prior use of support services and being from a culturally and linguistically diverse background contributed to age at identification of concern, age at diagnostic assessment and the likelihood of receiving a diagnostic assessment by 5 years. Electronic data capture had high acceptability, with 88.2% of caregivers reporting a preference for electronic completion of questionnaires.ConclusionsThe study shows a substantial delay in diagnostic assessments that leaves most vulnerable children without an assessment by school age and highlights contributors to delays. These delays highlight the complexity of delivering early intervention and support policies that rely on swift and appropriate developmental assessment to vulnerable families.